Allogene Accelerates Manufacturing Capacity for Upcoming Pivotal Trial

Date Published04/15/2022
Author NameAlex Keown
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Allogene Therapeutics
Parent companyAllogene Therapeutics
Type of work Manufacturing
Reshoring category:Reshoring
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Domestically, the work will be done:In-house
City reshored to:Newark
State(s) reshored to:CA
If relevant, work nearshored to:-
Product(s) reshoredCAR-T therapies, anti-CD19 AlloCAR T
Find Reshoring Articles